Show Summary Details
Page of

Testicular cancer 

Testicular cancer
Chapter:
Testicular cancer
Author(s):

Susanna Alexander

DOI:
10.1093/med/9780199664535.003.0017
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 20 August 2019

Testicular cancer has a high cure rate of approximately 95%. The typical presentation is in young adults aged 15-35 years. Orchiectomy is the standard of care and performed firstly unless there is life-threatening metastastic disease, and clinical diagnosis can be made by raised tumour markers. Postoperative treatment is based on the stage of the disease and histology (seminoma vs. non-seminoma). Residual masses can occur after chemotherapy in advanced clinical stages. These masses represent either residual disease or non-viable tissue. PET scan has in important role in predicting presence of viable disease in residual masses of in seminoma, especially if the mass is >3 cm. Because of the false negative results, PET has no established role in non-seminomatous residual disease.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.